

# Contact Dermatitis - Pipeline Review - 2019

<https://marketpublishers.com/r/C78FCE141778EN.html>

Date: December 2019

Pages: 120

Price: US\$ 1,250.00 (Single User License)

ID: C78FCE141778EN

## Abstracts

Firstview Insight's Contact Dermatitis - Pipeline Review-2019 provides an overview of the pipeline landscape of Contact Dermatitis. It provides comprehensive insights of all the clinical and non-clinical therapeutics in development with detailed description about the collaborations; deals; designations; patent information etc. These reports encourage the clients in distinguishing the upcoming and existing competitors in their separate therapeutic spaces. The report provides detailed description of the competitor profiles with key milestones and evidence along with analysis by mechanism of action; route of administration; molecule type; stage of development. Information obtained from multiple sources will be used to triangulate and update the profiles. The report also provides key events in the last year related to the indication. This report provides detailed analysis of all the products along with the companies involved.

Contact dermatitis is a red, itchy rash caused by direct contact with a substance or an allergic reaction to it. The rash isn't contagious or life-threatening, but it can be very uncomfortable.

Many substances can cause such reactions, including soaps, cosmetics, fragrances, jewelry and plants.

To treat contact dermatitis successfully, you need to identify and avoid the cause of your reaction. If you can avoid the offending substance, the rash usually clears up in two to four weeks. You can try soothing your skin with cool, wet compresses, anti-itch creams and other self-care steps.

### Symptoms

Image showing contact dermatitis on the face

Contact dermatitis on the face

Image showing poison ivy rash (allergic contact dermatitis)

Poison ivy blisters

Contact dermatitis usually occurs on areas of your body that have been directly exposed to the reaction-causing substance — for example, along a calf that brushed against poison ivy or under a watchband. The rash usually develops within minutes to hours of exposure and can last two to four weeks.

Signs and symptoms of contact dermatitis include:

A red rash

Itching, which may be severe

Dry, cracked, scaly skin

Bumps and blisters, sometimes with oozing and crusting

Swelling, burning or tenderness

### **Drug Profile Overview:**

The pipeline section provides descriptive drug profiles for the pipeline products including product description, mechanism of action, route of administration, molecule type, technology involved, chemical information.

### **Clinical Trial Overview:**

This section of the report focuses on the clinical activity of the molecule. It includes both clinical and pre-clinical activity which provides detailed information about the safety, efficacy, tolerability, toxicity of pipeline drugs. A graphical representation of the clinical trial landscape of pipeline therapy which includes information about phase of development, trial design, treatment arms, dosage and frequency, formulation of the drug, primary and secondary completion date, enrolment number, exclusion and inclusion criteria, line of therapy. This section also includes the clinical trial results and analysis based on those results.

### **Product Development Activity:**

This section of the report focuses on detail information about designations, exclusivity details, technology, licensing and collaboration, funding and financing, key milestones and various other development activities.

### **Company Overview:**

Company profile includes the detail about type of company, headquarter, global

presence, research focus and key financial

## **Scope**

The report provides a competitive landscape

The report also provides clinical trial landscape of the pipeline drugs including status; trial phase; sponsor type and end-point status

The report provides the list of companies which are the most active in the pipeline

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery

The report provides descriptive drug profiles which includes product description; comprising detailed mechanism of action (MoA); route of administration (RoA); Stage of development; clinical trial status; licensing and collaboration details & other developmental activities

The report features comparative analysis of product profiles based on molecule type; mechanism of action (MoA); route of administration (RoA)

The report summarizes all the dormant and discontinued pipeline projects

The report also provides latest news for the past one year

## **Reasons To Buy**

To identifying prominent players in the treatment landscape

To determine the drivers; barriers and unmet need in the treatment space

Gain strategically significant competitor information; analysis; and insights to formulate effective R&D strategies

Define in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business

potential and scope

To understand the composition of the pipeline in terms of molecule type;  
molecular target; mechanism of action and route of administration

### **List of products**

Tetrix

Bariederm

Dupilumab

MRX-6

EB01

NI-0801

BBI-2000

HPT-721

SIG-1322

WOL-071007

## Contents

### **1. DISEASE OVERVIEW**

- 1.1. Pathophysiology
- 1.2. Symptoms
- 1.3. Etiology
- 1.4. Diagnosis
- 1.5. Etiology
- 1.6. Treatment Algorithm
- 1.7. Treatment Options

### **2. FEATURED NEWS AND PRESS RELEASES, 2018-2058**

### **3. LIST OF COMPANIES DEVELOPING PRODUCTS FOR CONTACT DERMATITIS**

### **4. TREATMENT ALGORITHM**

### **5. CURRENT UNMET NEEDS**

### **6. MARKET TRENDS**

### **7. PIPELINE THERAPEUTICS**

### **8. THERAPEUTICS UNDER DEVELOPMENT BY COMPANIES**

### **9. LATE STAGE PRODUCTS (PHASE III)**

- 9.1 Drug 1
  - 9.1.1. Product Description
  - 9.1.2. Research and Development
  - 9.1.3. Product Development Activities
- 9.2. Drug 2
  - 9.2.1. Product Description
  - 9.2.2. Research and Development
  - 9.2.3. Product Development Activities

### **10. MID STAGE PRODUCTS (PHASE II)**

## 10.1 Drug 1

- 10.1.1. Product Description
- 10.1.2. Research and Development
- 10.1.3. Product Development Activities

## 10.2. Drug 2

- 10.2.1. Product Description
- 10.2.2. Research and Development
- 10.2.3. Product Development Activities

# **11. EARLY STAGE AND PRECLINICAL PRODUCTS (PHASE II)**

## 11.1 Drug 1

- 11.1.1. Product Description
- 11.1.2. Research and Development
- 11.1.3. Product Development Activities

## 11.2. Drug 2

- 11.2.1. Product Description
- 11.2.2. Research and Development
- 11.2.3. Product Development Activities

# **12. DRIVERS OF CONTACT DERMATITIS**

# **13. CONSTRAINTS OF CONTACT DERMATITIS**

# **14. THERAPEUTIC ASSESSMENT**

- 14.1. Assessment by Route of Administration
- 14.2. Assessment by Phase & Route of Administration
- 14.3. Assessment by Molecule Type
- 14.4. Assessment by Phase & Molecule type
- 14.5. Assessment by Target
- 14.6. Assessment by Mechanism of Action

# **15. COLLABORATIONS AND ACQUISITIONS DETAILS**

# **16. DORMANT PRODUCTS**

# **17. DISCONTINUED PRODUCTS**

**18. MARKET TRENDS**

**19. MARKET OPPORTUNITY ASSESSMENT**

**20. UNMET NEEDS**

**21. SWOT ANALYSIS**

**22. APPENDIX**

**23. REPORT METHODOLOGY**

**24. CONSULTING SERVICES**

**25. DISCLAIMER**

## List Of Tables

### LIST OF TABLES

Table 1: Marketed Contact Dermatitis drugs, 2019

Table 2: Sales of Marketed drugs

Table 3: Patent expiration details – marketed drugs

Table 4: Number of Products Under Development for Contact Dermatitis

Table 5: Products under Development by Companies

Table 6: Late Stage Products

Table 7: Mid Stage Products

Table 8: Early Stage Products

Table 9: Pre-Clinical and Discovery Products

Table 10: Assessment by Route of Administration

Table 11: Assessment by Stage and Route of Administration

Table 12: Assessment by Molecule Type

Table 13: Assessment by Stage and Molecule Type

Table 14: Assessment by Target

Table 15: Assessment by Mechanism of Action

Table 16: Dormant Products

Table 17: Discontinued Products



## List Of Figures

### LIST OF FIGURES

- Figure 1: Marketed and Pipeline Contact Dermatitis drugs, 2019
- Figure 2: Sales of Marketed drugs
- Figure 3: Patent expiration details – marketed drugs
- Figure 4: Number of Products Under Development for Contact Dermatitis
- Figure 5: Products under Development by Companies
- Figure 6: Late Stage Products
- Figure 7: Mid Stage Products
- Figure 8: Early Stage Products
- Figure 9: Pre-Clinical and Discovery Products
- Figure 10: Assessment by Route of Administration
- Figure 11: Assessment by Stage and Route of Administration
- Figure 12: Assessment by Molecule Type
- Figure 13: Assessment by Stage and Molecule Type
- Figure 14: Assessment by Target
- Figure 15: Assessment by Mechanism of Action
- Figure 16: Dormant Products
- Figure 17: Discontinued Products

## I would like to order

Product name: Contact Dermatitis - Pipeline Review - 2019

Product link: <https://marketpublishers.com/r/C78FCE141778EN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C78FCE141778EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970